Form S-3 - Registration statement under Securities Act of 1933:
SEC Accession No. 0001104659-24-130186
Filing Date
2024-12-19
Accepted
2024-12-19 16:31:41
Documents
17

Document Format Files

Seq Description Document Type Size
1 S-3 tm2431425-1_s3.htm S-3 279545
2 EXHIBIT 5.1 tm2431425d2_ex5-1.htm EX-5.1 9570
3 EXHIBIT 23.2 tm2431425d2_ex23-2.htm EX-23.2 1966
4 EX-FILING FEES tm2431425d1_ex-filingfees.htm   iXBRL EX-FILING FEES 17931
5 GRAPHIC lg_aclaristherapeutic-4c.jpg GRAPHIC 22456
6 GRAPHIC tm2431425d2_ex5-1img001.jpg GRAPHIC 9978
  Complete submission text file 0001104659-24-130186.txt   483181

Data Files

Seq Description Document Type Size
19 EXTRACTED XBRL INSTANCE DOCUMENT tm2431425d1_ex-filingfees_htm.xml XML 4758
Mailing Address 701 LEE ROAD SUITE 103 WAYNE PA 19087
Business Address 701 LEE ROAD SUITE 103 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

EIN.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-3 | Act: 33 | File No.: 333-283942 | Film No.: 241563786
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)